FDA Approves Juvederm Volux XC for Improvement of Jawline Definition

Allergan Aesthetics' Juvederm VOLUX™ XC has been given FDA approval for the improvement of jawline definition in adults over the age of 21.

It is worthy to note that JUVÉDERM® VOLUX™ XC IS THE FIRST AND ONLY HYALURONIC ACID (HA) FILLER TO RECEIVE U.S. FDA APPROVAL FOR IMPROVING JAWLINE DEFINITION.

JUVÉDERM® VOLUX™ XC complements the current line of products by offering even more cohesivity, lift, and form to provide a better jawline that appears more defined in person and on camera.

As a category leader, Juvederm’s collection of fillers offer the broadest portfolio of specifically designed treatment options, and this latest approval of JUVÉDERM® VOLUX™ XC marks the sixth product offering in the lineup alongside JUVÉDERM® VOLUMA® XC, JUVÉDERM®VOLLURE® XC, JUVÉDERM® Ultra Plus XC, JUVÉDERM® Ultra XC, and JUVÉDERM® VOLBELLA® XC.

In the pivotal clinical study, participants reported an 82% satisfaction with the appearance of their lower face and jawline through 12 months following treatment with JUVÉDERM® VOLUX™ XC.

Plump Medical Spa will be offering JUVÉDERM® VOLUX™ XC in early 2023 as it becomes available.